Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Ayoub

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Research Square|March 13, 2023
Mdm2/p53 levels in bone marrow mesenchymal stromal cells is essential for maintaining the hematopoietic niche in response to DNA damageRasoul Pourebrahim, Rafael Heinz Montoya, Zoe Alaniz, et al.
Cell Death & Disease|June 23, 2023
Mdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damageRasoul Pourebrahim, Rafael Heinz Montoya, Zoe Alaniz, et al.
Cell Reports|August 18, 2021
Mds1<sup>CreERT2</sup>, an inducible Cre allele specific to adult-repopulating hematopoietic stem cellsYi Zhang, Kathleen E McGrath, Edward Ayoub, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Niche-level immune evasion in <i>TP53</i> mutant AML residual disease revealed by spatial proteomicsHideaki Mizuno, Yuki Nishida, Andrea Bedoy, et al.
Nature Communications|October 14, 2018
EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcriptionEdward Ayoub, Michael P Wilson, Kathleen E McGrath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
The novel hypomethylating agent NTX-301 reprograms epigenetic and Hippo signaling pathways and exhibits pre-clinical activity in venetoclax-resistant and TP53-mutant AMLBing Z Carter, Po Yee Mak, Suresh Satpati, et al.
Research Square|March 4, 2025
BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) PathwayAmnon Peled, Michal Abraham, Hanna Wald, et al.
Medrxiv : the Preprint Server for Health Sciences|April 29, 2025
Somatic TP53 Mutations Drive T and NK Cell Dysfunction in AML and Can be Rescued by Reactivating Wild Type p53Li Li, Muharrem Muftuoglu, Edward Ayoub, et al.
Blood|December 8, 2023
Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022Francis Baumgartner, Constance Baer, Stefanos Bamopoulos, et al.
Blood Cancer Journal|April 23, 2023
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimeticsBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Research Square|March 13, 2023
Mdm2/p53 levels in bone marrow mesenchymal stromal cells is essential for maintaining the hematopoietic niche in response to DNA damageRasoul Pourebrahim, Rafael Heinz Montoya, Zoe Alaniz, et al.
Cell Death & Disease|June 23, 2023
Mdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damageRasoul Pourebrahim, Rafael Heinz Montoya, Zoe Alaniz, et al.
Cell Reports|August 18, 2021
Mds1<sup>CreERT2</sup>, an inducible Cre allele specific to adult-repopulating hematopoietic stem cellsYi Zhang, Kathleen E McGrath, Edward Ayoub, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Niche-level immune evasion in <i>TP53</i> mutant AML residual disease revealed by spatial proteomicsHideaki Mizuno, Yuki Nishida, Andrea Bedoy, et al.
Nature Communications|October 14, 2018
EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcriptionEdward Ayoub, Michael P Wilson, Kathleen E McGrath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
The novel hypomethylating agent NTX-301 reprograms epigenetic and Hippo signaling pathways and exhibits pre-clinical activity in venetoclax-resistant and TP53-mutant AMLBing Z Carter, Po Yee Mak, Suresh Satpati, et al.
Research Square|March 4, 2025
BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) PathwayAmnon Peled, Michal Abraham, Hanna Wald, et al.
Medrxiv : the Preprint Server for Health Sciences|April 29, 2025
Somatic TP53 Mutations Drive T and NK Cell Dysfunction in AML and Can be Rescued by Reactivating Wild Type p53Li Li, Muharrem Muftuoglu, Edward Ayoub, et al.
Blood|December 8, 2023
Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022Francis Baumgartner, Constance Baer, Stefanos Bamopoulos, et al.
Blood Cancer Journal|April 23, 2023
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimeticsBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Pageof 2